NextFin News - Breakout Ventures has closed its third flagship fund at $114 million, a capital injection specifically earmarked for the increasingly crowded intersection of artificial intelligence and "hard" sciences like biology and chemistry. The San Francisco-based firm, which traces its lineage back to a Thiel Foundation grant program, announced the close on Wednesday, marking a steady expansion from its $60 million debut in 2017 and its $112.5 million successor in 2021. This latest vehicle arrives as U.S. President Trump’s administration continues to emphasize domestic technological sovereignty, particularly in the race for AI-driven drug discovery and advanced materials manufacturing.
The fund’s timing is as much about market validation as it is about liquidity. Breakout’s recent track record provided the necessary momentum to navigate a fundraising environment that remains selective for mid-sized venture shops. The firm recently saw a significant exit with Surf Bio, a monoclonal antibody delivery specialist it backed as a lead investor, which was acquired by Halozyme for up to $400 million in January. That exit served as a proof of concept for Breakout’s thesis: that AI is no longer just a digital layer but the essential engine for navigating the "complexity of science," as Managing Director Lindy Fishburne noted during the launch.
Fund III has already begun deploying capital, with three seed-stage investments already finalized. The firm plans to build a portfolio of at least 20 companies, with check sizes ranging from a modest $500,000 for early experiments to $5 million for more established scientific platforms. This range reflects a strategic pivot toward "founder-led" science, where the principals are often PhDs commercializing their own research or industry veterans who have identified a specific friction point in the lab that only machine learning can smooth over. The investor base for this fund includes a mix of returning and new LPs, such as The Kraft Group, Pinegrove Venture Partners, and Korea Omega Investment Corporation, signaling a broadening institutional interest in "deep tech" that offers more than just SaaS-like margins.
The broader venture landscape is currently witnessing a bifurcation. While "generalist" AI funds are chasing the next large language model, specialized firms like Breakout are betting on the "application layer" of science. By focusing on biology and chemistry, Breakout is positioning itself in sectors where the data is proprietary and the barriers to entry are high. The promotion of Nima Ronaghi to partner alongside the fund’s launch further underscores this technical focus; Ronaghi’s background is emblematic of the firm’s requirement for deep domain expertise when evaluating startups that claim to use AI to fold proteins or synthesize new polymers.
This $114 million pool is relatively lean compared to the multi-billion dollar "mega-funds" being raised by the likes of General Catalyst or Spark Capital this year. However, in the world of early-stage science, such a size allows for a disciplined concentration of capital without the pressure to over-deploy into unproven markets. The challenge for Breakout will be the intensifying competition for these "science-first" deals, as traditional biotech VCs and tech-heavy firms increasingly collide in the same deal flow. For now, the firm is banking on its reputation as a specialized partner that understands the long R&D cycles and regulatory hurdles inherent in bringing a lab-grown innovation to the commercial market.
Explore more exclusive insights at nextfin.ai.
